Responses

PDF

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    MS may be a progressive disease occurring independently of exacerbations and remissions.

    I read the article on disability progression in patients with multiple sclerosis whether treated with interferon or not with interest(1)

    Although may of the placebo treated patients probably were treated with some form of immunomodulatory treatment after the study period, it certainly raises the question of whether neuronal progression in multiple sclerosis is due to accumulated deficits from exacerbations and re...

    Show More
    Conflict of Interest:
    None declared.